Jubilant Pharmova's Q1 FY 2025-26 Quarterly Results

Result Summary

• Jubilant Pharmova Ltd reported a 7.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.6%.
• Its expenses for the quarter were up by 5.8% QoQ and 7.1% YoY.
• The net profit decreased 265.9% QoQ and decreased 78.7% YoY.
• The earnings per share (EPS) of Jubilant Pharmova Ltd stood at 6.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Jubilant Pharmova Ltd is a diversified global pharmaceutical company engaged primarily in the development, production, and distribution of pharmaceutical products. The company is part of the pharmaceutical industry and offers a range of services and products including active pharmaceutical ingredients (APIs), generics, specialty pharmaceuticals, and contract research and development. As of the latest updates, Jubilant Pharmova has been focusing on expanding its portfolio and enhancing its research capabilities to cater to various therapeutic areas. Any recent major developments involving the company are not available in the provided data.

Revenue

For the first quarter of the fiscal year 2026 (Q1FY26), Jubilant Pharmova Ltd reported a total income of ₹1912.70 crores. This represents a quarter-over-quarter (QoQ) increase of 7.9% compared to the previous quarter (Q4FY25), where the total income was ₹1773.00 crores. Year-over-year (YoY), there is a 9.6% increase from the total income of ₹1745.70 crores reported in Q1FY25. These figures indicate a positive trajectory in revenue generation over both the quarterly and annual periods.

Profitability

Jubilant Pharmova Ltd's profitability metrics show significant variations over the reported periods. In Q1FY26, the company registered a Profit Before Tax (PBT) of ₹154.50 crores, which is a substantial turnaround from a loss of ₹57.10 crores in Q4FY25. However, this PBT reflects a 69.1% decrease compared to the ₹499.70 crores in Q1FY25. The Profit After Tax (PAT) for Q1FY26 stood at ₹102.50 crores, compared to a loss of ₹61.80 crores in Q4FY25 and a significant decrease from ₹481.80 crores in Q1FY25. The Earnings Per Share (EPS) in the current quarter was ₹6.50, contrasting with -₹3.70 in Q4FY25 and ₹30.40 in Q1FY25.

Operating Metrics

In Q1FY26, Jubilant Pharmova Ltd's total expenses amounted to ₹1758.20 crores, marking a QoQ increase of 5.8% from ₹1661.20 crores in Q4FY25 and a YoY increase of 7.1% from ₹1641.90 crores in Q1FY25. The tax expenditure for the quarter was ₹51.90 crores, which shows a significant rise both QoQ at 540.7% and YoY at 189.9%, compared to the respective values of ₹8.10 crores in Q4FY25 and ₹17.90 crores in Q1FY25. These metrics reflect the company’s operating cost dynamics and tax obligations over the reported periods.